期刊文献+

他汀类药物的心血管非降脂作用研究进展 被引量:7

Progress in Research into Cardiovascular Pleiotrophic Effects of Statins
下载PDF
导出
摘要 大量动物及临床实验都证明了他汀类药物的独立于降脂作用的心血管保护作用。他汀类药物可通过许多作用机制发挥其非降脂作用,我们将就这些方面做一综述。 Numerous animal and clinical studies support the presence of spectrum of beneficial effects for statins that are independent of their lipid lowering properties, that is, the cardiovascular pleiotrophic effects. The pleiotrophic effects of statins on cardiovascular disease are mediated by a variety of mechanisms, and have important and promising clinical potentials.
作者 刘德敏 崔炜
出处 《心血管病学进展》 CAS 2008年第5期814-816,共3页 Advances in Cardiovascular Diseases
关键词 他汀 非降脂作用 作用机制 statin, pleiotrophic effect, mechanism
  • 相关文献

参考文献30

  • 1Brouet A,Sonveaux P, Dessy C,et al. Hsp90 and eaveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins [ J ]. Circ Res, 2001,89 (10) :866-873.
  • 2Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance[J]. Circulation,2001,103( 1 ) :113-118.
  • 3Hattori Y, Nakanishi N, Akimoto K, et al. HMG-CoA reductase inhibitor increases GTP cyclohydrolase Ⅰ mRNA and tetrahydrobiopterin in vascular endothelial cells[ J]. Arterioscler Thromb Vasc Biol,2003,23 (2) : 176-182.
  • 4Yue TL, Gu JL, Wang C, et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy[J]. J Biol Chem,2000,275(48) :37895-37901.
  • 5Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study [ J ]. Circulation ,2003,108 ( 13 ) : 1560-1566.
  • 6Kleemann R,Princen HM, Emeis J J, et al. Rosuvastatin reduces atberosclerosis development beyond and independent of its plasma cholasterol-lowering effect in APOE * 3 -Leiden transgenie mice : evidence for antiinflammatory effects of rosuvastatin [ J ]. Circulation,2003,108 ( 11 ) : 1368-1374.
  • 7Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy[ J ]. N Engl J Med,2005,352 (1) :20-28.
  • 8Kaneyuki U, Ueda S, Yamagishi S, et al. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation [ J ]. V asc Pharmacol, 2007,46 ( 4 ) : 286 -292.
  • 9Lacut K,Oger E,le Gal G,et al.Statins bu not fibrates are associated with a reduced risk of venous thromboembolism:a hospital-based case-control study[ J ]. Fundam Clin Pharmacol,2004,18 (4) :477-482.
  • 10Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type Ⅲ nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice [ J ]. Stroke, 2000,31 ( 10 ) :2442- 2449.

同被引文献80

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部